Literature DB >> 12039993

Cumulative risk for developing end-stage renal disease in the US population.

Bryce A Kiberd1, Catherine M Clase.   

Abstract

The individual risk of developing end-stage renal disease (ESRD) and its overall impact on life expectancy is not known. This study's objectives were to determine the effect of ESRD on life expectancy for a cohort of 20-yr-olds and to compare this impact to that of several cancers for which population-based screening programs exist. A computer simulation, stratified by race (white, black) and by gender was used to calculate cumulative lifetime risk of ESRD, life-years lost to ESRD, and cumulative Medicare payments for ESRD. Similar calculations were made for breast, prostate, and colorectal cancer. The cumulative lifetime risk of ESRD for a 20-yr-old black woman is 7.8%. Equivalent risks for black men are 7.3%, white men 2.5%, and white women 1.8%. Lost years of life attributable to ESRD are 1.09, 1.10, 0.40, and 0.32 yr for black women, black men, white men, and white women, respectively. In blacks, ESRD is responsible for nearly as much loss of life-years as breast cancer in women and more loss of life-years than colorectal or prostate cancer in men. In addition, treatment costs for ESRD in this population are many-fold more expensive than cumulative treatment costs of these cancers. Exploring new screening and treatment strategies may be warranted to prevent ESRD, particularly in the US black population.

Entities:  

Mesh:

Year:  2002        PMID: 12039993     DOI: 10.1097/01.asn.0000014251.87778.01

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  46 in total

Review 1.  Target organ damage in African American hypertension: role of APOL1.

Authors:  Barry I Freedman; Mariana Murea
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

Review 2.  The aging kidney: a review--part II.

Authors:  Fred G Silva
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Age-dependent renal cortical microvascular loss in female mice.

Authors:  Victor H Urbieta-Caceres; Farhan A Syed; Jing Lin; Xiang-Yang Zhu; Kyra L Jordan; Caitlin C Bell; Michael D Bentley; Amir Lerman; Sundeep Khosla; Lilach O Lerman
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-07       Impact factor: 4.310

4.  Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations.

Authors:  Wen-Ya Ko; Prianka Rajan; Felicia Gomez; Laura Scheinfeldt; Ping An; Cheryl A Winkler; Alain Froment; Thomas B Nyambo; Sabah A Omar; Charles Wambebe; Alessia Ranciaro; Jibril B Hirbo; Sarah A Tishkoff
Journal:  Am J Hum Genet       Date:  2013-06-13       Impact factor: 11.025

5.  Placing Aboriginal kidney disease in context.

Authors:  Stephen P McDonald
Journal:  CMAJ       Date:  2013-12-02       Impact factor: 8.262

6.  Racial disparities in outcomes following PEA and asystole in-hospital cardiac arrests.

Authors:  Rabia R Razi; Matthew M Churpek; Trevor C Yuen; Monica E Peek; Thomas Fisher; Dana P Edelson
Journal:  Resuscitation       Date:  2014-12-09       Impact factor: 5.262

7.  Risk of ESRD in the United States.

Authors:  Patrick Albertus; Hal Morgenstern; Bruce Robinson; Rajiv Saran
Journal:  Am J Kidney Dis       Date:  2016-08-28       Impact factor: 8.860

Review 8.  Essential hypertension and risk of nephropathy: a reappraisal.

Authors:  Mariana Murea; Barry I Freedman
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-05       Impact factor: 2.894

9.  Lifetime risk of ESRD.

Authors:  Tanvir Chowdhury Turin; Marcello Tonelli; Braden J Manns; Sofia B Ahmed; Pietro Ravani; Matthew James; Brenda R Hemmelgarn
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

10.  Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.

Authors:  Julia J Scialla; Rulan S Parekh; Joseph A Eustace; Brad C Astor; Laura Plantinga; Bernard G Jaar; Tariq Shafi; Josef Coresh; Neil R Powe; Michal L Melamed
Journal:  Am J Nephrol       Date:  2015-08-20       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.